ContraFect Corporation Announces Proposed Public Offering of Common Stock and Warrants
May 21 2020 - 3:09PM
ContraFect Corporation (Nasdaq: CFRX), a clinical-stage
biotechnology company focused on discovering and developing direct
lytic agents for the treatment of life-threatening infectious
diseases, today announced that it has commenced an underwritten
public offering of shares of its common stock and warrants to
purchase additional shares of its common stock. The public
offering is subject to market conditions, and there can be no
assurance as to whether or when the public offering may be
completed, or the actual size or terms of the public offering. All
of the securities in the public offering are to be sold by
ContraFect.
ContraFect intends to use the net proceeds of
the public offering to continue funding its Phase 3 DISRUPT trial
of exebacase (CF-301) in Staph aureus bacteremia, including
right-sided endocarditis, to fund advancement of its portfolio,
including IND-enabling activities for CF-370, an engineered
gram-negative lysin directly targeting highly-resistant Pseudomonas
aeruginosa, and for working capital and other general corporate
purposes.
Mizuho Securities USA LLC and Cantor Fitzgerald
& Co. are acting as book-running managers for the public
offering.
The public offering is being made pursuant to an
effective shelf registration statement on Form S-3 that was filed
with the U.S. Securities and Exchange Commission (SEC) on November
30, 2018 and declared effective on December 13, 2018. A preliminary
prospectus supplement describing the terms of the public offering
will be filed with the SEC and will form a part of the effective
registration statement. Copies of the preliminary prospectus
supplement and accompanying prospectus relating to the public
offering may be obtained, when available, by contacting Mizuho
Securities USA LLC, Attention: Equity Capital Markets, 1271
Avenue of the Americas, 3rd Floor, New York, NY 10020, or by email
at US-ECM@us.mizuho-sc.com, or by telephone at (212) 205-7600 or
Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park
Avenue, 6th Floor, New York, NY 10022, or by email at
prospectus@cantor.com.
This press release shall not constitute an offer
to sell or a solicitation of an offer to buy the securities in the
public offering or the private placement, nor shall there be any
sale of these securities, in any state or other jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
the registration or qualification under the securities laws of any
such state or other jurisdiction.
Investor Relations Contact
Michael MessingerContraFect CorporationTel: 914-207-2300Email:
mmessinger@contrafect.com
ContraFect (NASDAQ:CFRX)
Historical Stock Chart
From Apr 2024 to May 2024
ContraFect (NASDAQ:CFRX)
Historical Stock Chart
From May 2023 to May 2024